Synaptic Dysfunction is Central to Dementia

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.

Dementia Isolates 50 Million Worldwide

Today there are few treatment options available for cognitive impairment. Syndesi is seeking to address this unmet need with an approach that is distinct from other therapies. While many are focused on developing disease-modifying therapies, we see a continuing need to effectively target the symptoms of dementia as patients will continue to suffer from impaired cognition.


Our Latest News


May 8, 2019

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI-118, in development for the treatment of cognitive impairment